胎儿中枢神经系统异常的产前外显子组测序分析
这项回顾性队列研究评估了产前外显子组测序(pES)在超声和/或MRI发现中枢神经系统(CNS)异常胎儿中的效用。在染色体微阵列分析(CMA)阴性的167例妊娠中,pES检出致病或可能致病变异42例(25.1%);非孤立性CNS异常胎儿的诊断率显著高于单一CNS异常胎儿(35.7% vs 14.5%,P=0.010),且pES结果显著影响父母终止妊娠的决策。
要点
- CMA阴性且超声和/或MRI发现CNS异常的胎儿中,pES检出致病或可能致病变异42/167(25.1%)。
- 非孤立性CNS异常胎儿的pES诊断率高于单一CNS异常胎儿(35.7% vs 14.5%,P=0.010)。
- 胎儿携带致病或可能致病变异时,父母选择晚期终止妊娠的比例高于不确定性变异、次要/偶然发现或pES阴性者(83.3% vs 41.3%,P<0.001)。
核心结论
- 对于CMA未发现染色体异常或拷贝数变异的CNS异常胎儿,pES提高了遗传性疾病的确诊率,无论CNS异常数目多少及是否合并颅外异常;pES结果可显著影响父母的决策。
研究设计与样本
- 回顾性队列研究,纳入产前超声和/或磁共振成像发现CNS异常的胎儿167例;所有胎儿先行CMA,CMA确认非整倍体或致病性拷贝数变异者不进行pES并排除,CMA阴性者接受pES检测。
诊断标准与关键数值
- CMA阴性且超声和/或MRI发现CNS异常的胎儿中,pES检出致病或可能致病变异42/167(25.1%)。
- 非孤立性CNS异常胎儿pES诊断率35.7%(20/56),单一CNS异常胎儿14.5%(8/55),P=0.010。
- 胎儿存在三个或以上CNS异常时,pES阳性诊断率增至42.9%。
- 42例检出变异中,25/42(59.5%)为新发突变,其余为遗传性突变且携带显著复发风险。
临床应用与阅片要点
- 对于CMA阴性、超声和/或MRI发现CNS异常的胎儿,pES可提高遗传性疾病检出率,无论CNS异常数目及是否合并颅外异常。
- pES检出致病或可能致病变异时,父母选择晚期终止妊娠的比例为83.3%(25/30),高于不确定性变异、次要/偶然发现或pES阴性者的41.3%(38/92),P<0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the utility of prenatal exome sequencing (pES) in fetuses with central nervous system (CNS) abnormalities.
METHODS: This was a retrospective cohort study of fetuses identified to have CNS abnormality on prenatal ultrasound and/or magnetic resonance imaging. All fetuses were first analyzed by chromosomal microarray analysis (CMA). Fetuses with a confirmed aneuploidy or causal pathogenic copy-number variant (CNV) on CMA did not undergo pES analysis and were excluded, while those with a negative CMA result were offered pES testing.
RESULTS: Of the 167 pregnancies included in the study, 42 (25.1%) were identified to have a pathogenic or likely pathogenic (P/LP) variant. The diagnostic rate was significantly higher in fetuses with a non-isolated CNS abnormality than in those with a single CNS abnormality (35.7% (20/56) vs 14.5% (8/55); P = 0.010). Moreover, when a fetus had three or more CNS abnormalities, the positive diagnostic rate increased to 42.9%. A total of 25/42 (59.5%) cases had de-novo mutations, while, in the remaining cases, mutations were inherited and carried a significant risk of recurrence. Families whose fetus carried a P/LP mutation were more likely to choose advanced pregnancy termination than those with a variant of uncertain significance, secondary/incidental finding or negative pES result (83.3% (25/30) vs 41.3% (38/92); P < 0.001).
CONCLUSION: pES improved the identification of genetic disorders in fetuses with CNS anomalies without a chromosomal abnormality or CNV identified on CMA, regardless of the number of CNS anomalies and presence of extracranial abnormality. We also demonstrated that pES findings can significantly impact parental decision-making. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Zhi Y, Liu L, Wang H, et al. Prenatal exome sequencing analysis in fetuses with central nervous system anomalies. Ultrasound Obstet Gynecol. 2023. PMID: 37204857. doi:10.1002/uog.26254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。